Results 1 to 10 of about 622 (134)

Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real-world clinical practice. [PDF]

Epileptic Disord
Abstract Objective Patients with drug‐resistant epilepsy (DRE) typically take multiple anti‐seizure medications (ASMs) and are at risk of treatment‐related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug‐resistant epilepsy.
Benavente ÁS, Martín GG, Ruiz EDC, García PC, Moreno YL, María JCE, Fuentes IL, Conti SN, Calle RC, Cabrera AF, González IR, Blanco DC, Muñoz MIC, Castro PJS.   +13 more
europepmc   +2 more sources

Induction of cytochrome P450 2C9 and P-glycoprotein activity by antiseizure medications: A systematic review and network meta-analysis. [PDF]

Epileptic Disord
Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Cohen H, Bahash N, Ben-Shushan T, Matok I, Eyal S.   +4 more
europepmc   +2 more sources

Effectiveness of adjunctive low-dose clobazam in adults with focal drug-resistant epilepsy and incomplete response to cenobamate: A real-world study. [PDF]

Epilepsia Open
Abstract Objective Cenobamate (CNB) is a highly effective antiseizure medication (ASM) for focal drug‐resistant epilepsy (DRE); nevertheless, even with CNB treatment and optimized therapy, a substantial proportion of patients continued to experience seizures.
Ciullo I, D'Aniello A, Panzini C, Salamone EM, Quarato PP, Grammaldo LG, Dal Pozzo M, Abeni D, Di Gennaro G.   +8 more
europepmc   +2 more sources

Cenobamate for Difficult-to-Treat Epilepsy - Selected Case Vignettes. [PDF]

Neuropsychiatr Dis Treat
Epilepsy affects millions worldwide, presenting unique challenges in specific populations such as the elderly, children, and patients with comorbidities or drug-resistant forms. Tailored approaches addressing unmet needs in these subgroups are critical to improving outcomes.This research uniquely integrates real-world evidence and detailed case ...
Villani F, Dono F, Operto FF, Pignatta P, Puligheddu M, Stipa C, Zanoni T.   +6 more
europepmc   +4 more sources

Rapid recovery after intrathecal dexamethasone in FIRES. [PDF]

Epileptic Disord
Epileptic Disorders, Volume 28, Issue 3, Page 884-887, June 2026.
Nico JF, Fradique AR, Teixeira C, Moinho R, Marques ML, Santos C, Ribeiro JA, Palavra F, Pereira C.   +8 more
europepmc   +2 more sources

Cenobamate Monotherapy for Focal Epilepsy: A Single-Center Retrospective Study. [PDF]

Neurol Clin Pract
Cenobamate is a novel antiseizure medication (ASM) approved by the Food and Drug Administration for use as adjunctive therapy in focal epilepsy. However, there are limited data on its use as a standalone monotherapy. The aim of our study was to investigate the use of cenobamate monotherapy and evaluate its clinical efficacy and safety in treating focal
Zengin E, Erol F, Gil Guevara A, Lado FA.   +3 more
europepmc   +3 more sources

Delayed and deferred surgery associated with cenobamate use in people with drug‐resistant focal epilepsy

Epilepsia, EarlyView.
Abstract Objective Cenobamate has been shown to be an effective antiseizure medication for some patients with drug‐resistant focal epilepsy being considered for epilepsy surgery. This retrospective single‐center study evaluated whether surgery was obtained within 12 months for patients who received cenobamate as a treatment during the presurgical ...
Jacob Pellinen, Stefan Sillau, Aimee Bui, Alexandra Danciutiu, Lesley Kaye, Ashvin Sood, Louis Ferrari, William E. Rosenfeld, Christopher Elder   +8 more
wiley   +1 more source

Management of ring chromosome 20 syndrome: Narrative review and consensus recommendations

Epilepsia, EarlyView.
Abstract Ring chromosome 20 (ring 20) is a rare genetic condition usually presenting as developmental and epileptic encephalopathy. The disease is caused by fusion of the long and short arms of chromosome 20. Patients are symptomatic even if there is no loss of genetic material.
Asma Khamis, Emilia Ricci, Maria Paola Canevini, Lieven Lagae, Kentaro Tokumoto, Yushi Inoue, Tim Buckinx, Allison Watson, Kenneth A. Myers   +8 more
wiley   +1 more source

Corticocortical evoked potential amplitude is altered by cortical stimulation in epilepsy

Epilepsia, EarlyView.
Abstract Objective Neurostimulation is an established therapy for drug‐resistant epilepsy, but optimizing stimulation parameters remains a major challenge. Corticocortical evoked potential (CCEP) amplitude may serve as an immediate biomarker of neurostimulation effects, enabling rapid parameter optimization.
Bethany J. Stieve, Aaron F. Struck, Dillon Scott, Richard Chappell, Andrew T. Knox   +4 more
wiley   +1 more source

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy

Epilepsia, EarlyView.
Abstract Objective In patients with drug‐resistant epilepsy who undergo anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS), efficacy is assessed months after therapy initiation and clinicians have no guidance when choosing stimulation parameters due to the lack of real‐time biomarkers.
Zachary T. Sanger, Xinbing Zhang, Thomas Lisko, Hafsa Farooqi, Steffen Ventz, Sandipan Pati, Thomas R. Henry, David P. Darrow, Michael C. Park, Theoden I. Netoff, Robert A. McGovern   +10 more
wiley   +1 more source